Q&A with Craig Misrach, President and Board Member at UpLyft

Media 7 | December 8, 2020

Craig Misrach, President and Board Member at UpLyft joined the organization in 2018, spearheading the company's product launch and commercialization efforts. He began his career at Deloitte where he audited various lower middle-market businesses as a Senior Accountant.

Maintaining an active Certified Public Accountant (CPA) license, Mr. Misrach serves on the Board of Directors of Aculief and the Jewish Community Foundation, San Diego.

MEDIA 7: Could you tell us about your career journey from Deloitte to UpLyft?
CRAIG MISRACH:
I started my career at Deloitte as a public accountant and auditor just trying to get the work experience necessary to obtain my CPA license in the State of California. Little did I know how working in janitor closets at client’s office locations whereby doing your job entailed asking questions and information requests from people who didn’t want to talk to you could build so much character!

I left Deloitte to join my client Silvergate Bank where I was the Controller in charge of managing ~$500M in assets at the age of 25. Not only did I gain management responsibility at Silvergate overseeing and working with a staff of 9 individuals, but I also was able to observe first-hand what it was like working in a fast-paced growing entrepreneurial culture as we grew from ~20 to ~70 employees in a short two year period.

I decided to go obtain my MBA at the University of Virginia to round out my skill sets and start a new business from the ground up. This was not a traditional path to do so at the time as most graduate students would go get their MBA from a top-tier program to become an investment banker, management consultant, or marketing manager at a Fortune 500 company. I knew from the time early in my career, and in watching my father start his own real estate business growing up in Ohio, that with hard work and perseverance I could start a successful business from the ground up.

I started my first venture, Freedom Meditech, by way of learning about the diabetes field in my MBA program and researching the reasons why it was still status quo (not just in 2006 but also still today 15 years later) for people with diabetes to be pricking their finger to determine their blood glucose information. I thought that was so archaic and not fair to such individuals when there was better technology available (subject to FDA compliance) to obtain this information non-invasively.

I spent 8+ years as the Founding CEO of Freedom Meditech, where under my leadership, we became the 1st company in the world to obtain FDA clearance for a non-invasive diabetes diagnostic test. The test worked by shining light in a person’s eye for 6 seconds. It was truly revolutionary and the FDA clearance we obtained (the first in the world – we estimated $1B of venture capital went into failed attempts of companies to obtain this FDA clearance and commercialize) was likely one the proudest moments in my career because it was a team effort and a culmination of hard work, numerous late nights, and extremely tough decisions along the way of reducing to practice a prototype, conducting clinical studies, analyzing data, and performing this process all over again several times to support our FDA submission. We built an entire sales organization, international distribution network, sold millions of dollars of product around the world, and then eventually sold the business to Sinocare LTD in China. Our product (ClearPath DS-120) is still used to this day to early detect diabetes and pre-diabetes in patients by clinicians all over the world.
The past 5 years I have spent “giving back” to entrepreneurs and the community by way of participating on Boards of Directors and mentoring aspiring entrepreneurs. This includes positions I have held as a board member on Aculief (sold – June 2020), as a Business/Finance mentor for the San Diego Sports Innovation network, and as a Board Member for the Jewish Community Foundation in San Diego.

I was introduced to UpLyft and our Founder in 2018. I was skeptical at first of the product mostly because I was not familiar with the field and I did not have a frame of reference for how “unique” UpLyft was or the value proposition it embodied. With an investor mentality, I performed due diligence on the durable medical equipment (DME) landscape, other “lifts” on the market for transferring individuals from bedside to wheelchair, and the size of the market opportunity in the US and around the world. Additionally, I had the benefit of being introduced to the company by my contract manufacturer at my last venture (who was slated to be the contract manufacturer for UpLyft), and that helped gain the confidence that we could manufacture UpLyft with impeccable quality, reasonable cost basis, and in a reasonable timeline. I then signed on to be UpLyft’s President and CEO and since that time we have raised capital, performed extensive customer validation (both for the direct to consumer home market and the for the institutional healthcare facility marketplace), accepted pre-orders from customers, and now are staging the business and technology for mass manufacturing in an FDA-compliant manner.

M7:  UpLyft is the world’s first Self Transfer System from bed to wheelchair for people with limited mobility. What are the challenges you faced to launch a high-tech innovation like this?
CM:
Just like any pre-revenue medical device venture, capitalization is key, and you need to kiss a lot of frogs to obtain the capital necessary to invest in manufacturing so you can mass scale your product. Some refer to this as the valley of death. Initially, we were getting lots of questions on customer validation. Things like “the data suggests this will be a huge success, but we have no proof that customers will be this.” Accordingly, we embarked on several initiatives including:

1. Circulation of surveys to potential customers (and family members, caregivers, and healthcare facility workers) to ascertain what was most important from a product feature, utility, and pricing perspective. Check out our B2B Healthcare Facilities for Nurses/Caregivers.
2. Providing in-person demonstrations where we captured testimonials of use and purchase interest.
3. Creating video content of UpLyft in use (seeing is believing).
4. After securing some angel capital that we could devote to efforts outside of R&D prototype creation and patent filing costs, we were able to establish a digital footprint in 2020 (website, order taking capability, e-mail outreach, social media utility, and engagement) whereby actual customer interest could be measured via open pre-order commitments.

With this customer validation now in hand, we believe we can be successful in obtaining the necessary capital (and reducing financing risk) to commence manufacturing and finally provide our pre-order customers and other potential customers a delivery date certain so they have the confidence to place a deposit with us and manufacture and deliver products to them.


Technology is upgrading the healthcare ecosystem by providing more efficient and safe alternatives to labor-intensive procedures.

M7: In your opinion, how is technology upgrading the healthcare ecosystem?
CM:
Technology is upgrading the healthcare ecosystem by providing more efficient and safe alternatives to labor-intensive procedures. In the case of UpLyft, we reduce the number of patient-lifting injuries for healthcare workers. Technology growth within the healthcare system also allows for individuals suffering from illnesses and mobility challenges to live normal lives, as technology can act as a replacement for body parts, organs, muscles, and so on. This can allow patients to regain a sense of independence and joy of living.

M7: Could you tell us about some developments at UpLyft that all of you are excited about?
CM:
UpLyft is the first FDA-compliant self-transfer system from bed to wheelchair for people with limited mobility. This is a technology that can not only help seniors and the elderly as a fall prevention tool in a world where baby boomers want to live at home longer and defer going into a nursing home or assisted living – but it also helps restore independence and autonomy where otherwise a person cannot start their day by getting out of bed without a caregiver or risk falling or getting injured. We are also excited to be bringing to market a product that can help people with obesity (now almost 1/3 of the US population), late-stage diseases such as multiple sclerosis, Parkinson’s disease, or cerebral palsy, and for those who have been in accidents and now manage spinal cord injuries (e.g. paralysis) and mobility has been compromised. Thus, UpLyft can be a long-term purchasing solution for families or a short-term rental option for those managing end of life care.
Our patent estate continues to grow which further solidifies UpLyft’s unique offering and positioning in the marketplace. Most recently we were awarded our design patents in China and Japan – historically very challenging markets to get patents issued. Take a look at our assisted transfer demonstration, and more on it here.

We are also excited about our initial product demand after just a short 60 day period of going “live” late this summer with UpLyft commercialization. We had to “turn off” the digital marketing for pre-orders as we secured more than we expected and now we have to raise the rest of the necessary capital to get our manufacturing up and running. We didn’t want to be in a position where we couldn’t relay to potential customers a delivery date.
Lastly, we are finishing off our crowdfunding campaign on WeFunder which we have been conducting for the past several months where we raised $200K in the capital. As of this writing, of all active campaigns on WeFunder we are the:
#1 most funded healthcare company
#2 most funded medical device company
#3 most funded manufacturing company
#4 most funded B2C technology (Check out our B2C Direct To Consumer for Home Use technology)

We are crowdfunding!! Invest here


Sell product benefits, not features. A customer wants to know how it will benefit them, not how “cool” a certain feature was engineered.

M7: How has the COVID-19 pandemic affected your work - what day to day processes have you had to re-tool to be able to pull them off remotely?
CM:
We were operating as a virtual company before the COVID pandemic so not much has changed relative to employee engagement and our team being able to do their job. Obviously from March through June, the capital markets had temporarily evaporated for early-stage capital, and getting an audience in July/August this year was even tough. Now that we are operating in a new normal, we have had to re-tool the way we go about raising capital. One way we did that was by conducting a crowdfunding campaign on WeFunder. This launched in August and is on the cusp of closing and we have secured $200,000 by doing so. This effort forced us to go out and create more digital content which has (and will continue) to provide us benefit with sales efforts for potential customers over social media, our website, and via e-blasts.

M7: What marketing channels do you use, and which ones do you see as the most promising given your target customers?
CM:
The durable medical equipment (DME) field has been notorious for many of its outdated methods to reach customers, relying on physician scripts (prescriptions), the use of intermediary distributors, mandatory need for insurance reimbursement, and thus giving margin away through the supply chain and making it a hassle for purchase for consumers.

When we set out with our commercialization efforts for UpLyft not only were we committed to developing a novel product with its patent positioning, but we also have been committed to disrupting the way a medical product like this can be sold directly to the consumer.
Accordingly, our strategy of bringing to market a cash-pay product that can easily be financed with easy monthly payments (no insurance reimbursement necessary), FDA-compliance that does not require a doctor’s prescription and accessed DIRECTLY by consumers with the original equipment manufacturer, we believe can create stickiness with our customers long-term as we expand our product offering. This could not be made possible without the direct fulfillment capabilities of our contract manufacturer here in San Diego and our robust digital footprint we have created via our website and socials.

Thus, the marketing channels we currently use include our website, Facebook, Instagram, Twitter, and crowdfunding platforms. This gets us directly in front of the eyeballs of people who are in a HEALTH CRISIS (or helping manage a loved one’s health crisis).


A transaction is never done until the money has been wired – so keep your pedal on the gas until that has been completed!

M7: What have you learned from your previous experiences, especially with regard to negotiations and deal-making? Do you have any tips for our readers who wish to ace these skills?
CM:
1. Raising capital, closing product sales, and selling a business are all unique skill sets which at times can be more art than science. Relationships matter and building those relationships can be key in getting a deal across a finish line.
2. Time is of the essence. You may not want/need to emphasize this to the party across the table but your sense of urgency should always have “time” top of mind because you never know when a financial crisis, global pandemic, or other “capital evaporation” event can occur (and the door can shut quickly!). Just remember, any economic downturn or even temporal global or domestic event can cause certain investors to pause.
3. Communicate an expected/anticipated timeline to investors at the beginning of the process. Simply ask “would you like to know how we typically work from here with people that successfully become investors in our company”? They won’t say no to you. And that can give you the opportunity to state a 60-day timeline (e.g. angles) or a 90-120 window if you are working with an institutional investor.
4. Sell product benefits, not features. A customer wants to know how it will benefit them, not how “cool” a certain feature was engineered.
5. It's OK to give in a negotiation. Sometimes it's best to “give” something upfront without a quid pro quo. This can set a better tone for the remainder of the negotiation.
6. Don’t start a negotiation with the most pressing/important item to you. It may not be wise to show your hand in this regard. Many times, I start with easy/non-essential items just to test the pulse.
7. When you have a potential investor who is continuing to ask for things at the end of a negotiation one way to cut it off is by saying “If we can accommodate this item for you, do we have a deal?” If the investor continues to run down items in continuing fashion, interaction after interaction (and has new items each time) it's likely not the best investor for you.
8. If you do not have a good feeling about an investor – reject them. There are other fish in the sea. Many will reject you too so remember it’s a two-way street!
9. An investor (especially a large one) is going to be a partner. It is not just about their money. Do due diligence on them, ask other CEO’s what it’s like to have them as an investor or board member, and “test” them in various fashions to see if they are going to be reciprocal in a give and take fashion. It is more valuable to know what investors to stay away from than what investors to go to.
10. A transaction is never done until the money has been wired – so keep your pedal on the gas until that has been completed!

ABOUT UPLYFT

UpLyft™ is the first known FDA-compliant Self Transfer System (“STS”) from bed to wheelchair for people with limited mobility. In 1 minute, a person can self-transfer him/herself with UpLyft™ from a flat (supine) position in bed into their wheelchair or vice versa. UpLyft™ replaces slings, body boards, and other inferior “lift to stand” mechanisms that require nursing assistance and physical force to transfer individuals with mobility challenges.

More THOUGHT LEADERS

Q&A with Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva

Media 7 | September 17, 2021

Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva, is responsible for working with the pharmaceutical industry to improve current workflows with innovative bioanalytical solutions. He also advises on R&D projects and business development activities. Fredrik is the author of several publications on drug discovery and biosimilar strategies. He is also a member of an EMEA Pharmaceutical Industry Expert Panel, and he lectures and discusses regulatory issues with government officials and health authorities....

Read More

Q&A with Cecil Nick, Vice President at Parexel

Media 7 | August 2, 2021

Cecil Nick, Vice President (Biotechnology) at Parexel, is a biochemistry graduate and regulatory professional with over 30 years experience specializing in the clinical development of biological and biotech products. He has supported 7 biosimilar marketing approvals and has over 80 biosimilar Agency interactions in EU, US, Canada and RoW. He offers extensive expertise to clients with respect to biosimilars, comparabilty, clinical development, orphan drugs and training. He is a fellow of TOPRA and has been a guest lecture at Cardiff University for MSc in Clinical Research, and Greenwich University for MSc in Pharmaceutical Sciences, courses and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has over 30 publications to his name....

Read More

Botco.ai's Co-Founder & Executive Chairman, Anu Shukla says, 'Instant' is the new mantra

Media 7 | November 15, 2021

Anu Shukla, Co- Founder & Executive Chairman at Botco.ai explores the latest features on Botco.ai 2.0 and how it helps marketers in health and wellness verticals make more personalized, analytical and actionable insight-driven campaigns. Read on to find out about the biggest challenges in the current COVID-19 influenced product marketing landscape....

Read More

Q&A with Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva

Media 7 | September 17, 2021

Fredrik Sundberg, Global Director Strategic Customer Relations at Cytiva, is responsible for working with the pharmaceutical industry to improve current workflows with innovative bioanalytical solutions. He also advises on R&D projects and business development activities. Fredrik is the author of several publications on drug discovery and biosimilar strategies. He is also a member of an EMEA Pharmaceutical Industry Expert Panel, and he lectures and discusses regulatory issues with government officials and health authorities....

Read More

Q&A with Cecil Nick, Vice President at Parexel

Media 7 | August 2, 2021

Cecil Nick, Vice President (Biotechnology) at Parexel, is a biochemistry graduate and regulatory professional with over 30 years experience specializing in the clinical development of biological and biotech products. He has supported 7 biosimilar marketing approvals and has over 80 biosimilar Agency interactions in EU, US, Canada and RoW. He offers extensive expertise to clients with respect to biosimilars, comparabilty, clinical development, orphan drugs and training. He is a fellow of TOPRA and has been a guest lecture at Cardiff University for MSc in Clinical Research, and Greenwich University for MSc in Pharmaceutical Sciences, courses and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has over 30 publications to his name....

Read More

Botco.ai's Co-Founder & Executive Chairman, Anu Shukla says, 'Instant' is the new mantra

Media 7 | November 15, 2021

Anu Shukla, Co- Founder & Executive Chairman at Botco.ai explores the latest features on Botco.ai 2.0 and how it helps marketers in health and wellness verticals make more personalized, analytical and actionable insight-driven campaigns. Read on to find out about the biggest challenges in the current COVID-19 influenced product marketing landscape....

Read More

Related News

HEALTH TECHNOLOGY

athenahealth Implements DrFirst’s Digital Engagement Solution to Encourage Patients to Follow Prescribed Treatment Plans

athenahealth, Inc. | August 03, 2022

athenahealth, a leading provider of network-enabled software and services for medical groups and healthcare organizations nationwide, and health technology pioneer, DrFirst, today announced they are partnering to help improve medication adherence and patient outcomes. athenahealth’s large user base will now be able to send patient medication notifications powered by DrFirst’s RxInform to reduce prescription abandonment and help patients adhere to their recommended medication therapies. Patients abandon 20% to 30% of new prescriptions, whether due to high out-of-pocket costs, concerns about side effects, procrastination, or other factors. This lack of medication adherence can lead to increased total cost of patient care and undesirable health outcomes, such as disease progression, hospitalization, or even death. Now, the athenahealth electronic health record system that helps providers maximize clinical productivity and focus on delivering high-quality care to patients connects with RxInform, which automatically triggers a secure message to a patient’s mobile device when a clinician sends a prescription order to a pharmacy. From the message, patients may receive cost savings opportunities as available for a prescribed therapy and can view detailed information regarding their prescriptions, with a focus on behavioral and educational issues that have been proven to reduce prescription abandonment. The experience is seamless for the prescriber and helps them ensure the best outcomes for their patients. “We are always looking for innovative ways to drive better results for our customers and their patients – especially as the industry shifts more toward value-based care. Every provider wants to minimize prescription abandonment rates because non-adherence to medication regimens negatively affects desired clinical outcomes. By adding RxInform to the latest release of athenaOne, we are immediately giving all our providers an automated function within their established prescribing workflows to support better patient outcomes.” Paul Brient, chief product officer for athenahealth Since 2017, RxInform has received more than three million patient ratings, with 92% overall positive scores. These results indicate that patients welcome these messages, presenting new opportunities for providers to nurture patient relationships and build loyalty outside of the exam room. “Primary care providers and specialists who care for high-risk patients need tools to help people take their medications as prescribed,” said G. Cameron Deemer, president of DrFirst. “We’re pleased to partner with athenahealth to give its network of approximately 145,000 providers access to the RxInform platform so they can help patients overcome the common hurdles that lead them to abandon their medications at the pharmacy.” About athenahealth, Inc. athenahealth creates innovative healthcare technology that connects clinicians, patients, payers, and partners in differentiated ways. Our electronic health records, revenue cycle management, and patient engagement tools allow anytime, anywhere access, driving better financial outcomes for our customers and enabling our provider customers to deliver better quality care. In everything we do, we’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. About DrFirst Since 2000, DrFirst has pioneered healthcare technology solutions and consulting services that securely connect people at touchpoints of care to improve patient outcomes. We create unconventional solutions that solve care collaboration, medication management, price transparency, and adherence challenges faced in healthcare. We unite the Healthiverse—the interconnected healthcare universe—by providing our clients with real-time access to the information they need, exactly when and how they need it, so patients get the best care possible. DrFirst solutions are used by nearly 325,000 healthcare professionals, including 220,000 prescribers, 70,000 pharmacies, 290 HIS/EHRs, and 1,500 hospitals in the U.S. and Canada.

Read More

HEALTH TECHNOLOGY

BD Acquires MedKeeper to Offer Cloud-based, Connected Pharmacy Software

BD | July 29, 2022

BD a leading global medical technology company, announced today it has acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications. MedKeeper strategically complements BD's existing presence in the pharmacy – where the company has pioneered solutions in compounding, logistics workflow, controlled substance management and inventory optimization. MedKeeper's platform will become part of the company's existing portfolio of connected medication management capabilities. By combining MedKeeper's platform with BD's broad technology expertise, the companies will work to optimize the preparation of compounded medications – a critical need in the pharmacy today. "Preparing the right dose for patients requires a combination of factors – including personnel, training, and compliance. Pharmacy leaders require IV workflow management technology that is personalized to their needs and works within their environment. Adding MedKeeper to our portfolio will enable us to offer our customers easy to use, customizable solutions that make meaningful and incremental progress in IV workflow management." Mike Garrison, Worldwide President of Medication Management Solutions at BD Today, many pharmacies leverage a combination of both manual and technical tools for their IV workflow management system. Adding MedKeeper to BD's Medication Management Solutions portfolio will further strengthen the company's ability to deliver solutions that best meet customers' needs – now and in the future. "Demands in today's pharmacy environment, such as COVID-impacted labor shortages and changing regulatory requirements, have further exacerbated the need for customizable pharmacy software solutions to support flexible, directed workflow, inventory tracking and reporting needs in sterile and non-sterile compounding," said Garrison. "Manual, time-consuming procedures that might once have been 'good enough' now can be replaced and augmented by software that enables pharmacists to provide a higher standard of care." BD and MedKeeper will work to provide customers with flexibility and capabilities in meeting industry standards for preparing compounded medications, incorporating the latest regulatory guidance. Together, the companies are dedicated to ensuring that every customer has a workflow solution that best supports their environment and delivers efficiencies to their frontline clinicians. The transaction is expected to be immaterial to BD's fiscal 2022 financial results. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Read More

HEALTH TECHNOLOGY

KAID Health Technology Demonstrates the Value of Natural Language Processing to Improve Preoperative Care

KAID Health | August 02, 2022

KAID Health, an AI-powered health care data analysis and provider engagement platform, announced the results of a study that validates the potential utility of its Natural Language Processing technology to improve provider efficiency and care quality. The peer-reviewed “doctor vs. artificial intelligence” paper found that KAID Health’s NLP technology greatly aligned with the clinician reviewers in completing a pre-operative checklist, and further was able to identify 16.6% of instances where the presence or absence of a specific condition was not found by the anesthesiologist. The research study was undertaken at UCSD’s Department of Anesthesiology, Division of Perioperative Informatics. The authors of the manuscript were Harrison S. Suh, BS, Jeffrey L. Tully, MD, Minhthy N. Meineke, MD, Ruth S. Waterman, MD, MS, and Rodney A. Gabriel, MD, MAS. “We have demonstrated that NLP technology can help identify critical medical conditions relevant to preanesthetic evaluation. Key to this was KAID Health’s ability to utilize unstructured free-text input from the electronic medical record to flag critical medical conditions for anesthesiologists,” researcher and senior author Dr. Rodney Gabriel explained. “This research shows that NLP may be a useful tool to aid preoperative anesthesia providers in screening and evaluation of surgical patients.” For each of the 93 patients in the study, researchers collected all pertinent free-text notes from the EMR. The free-text notes were then processed by a Named Entity Recognition pipeline, which incorporated an NLP machine learning model developed by KAID Health. The model recognizes and labels spans of text that correspond to medical concepts. Medical concepts were then mapped to a list of medical conditions that were of interest for a preanesthesia evaluation. The most common conditions that the NLP pipeline captured that the anesthesiologist did not include cardiac arrhythmias, angina, anticoagulation, peripheral vascular disease, obstructive sleep apnea, and neuromuscular disease. “We are proud that leading academic institutions, such as UCSD, are partnering with KAID to ensure our NLP and AI models meet the demanding accuracy and usability standards required of the industry. KAID Health’s NLP technology played a vital role in this study in identifying pertinent preanesthesia history to optimize efficiency for anesthesiologists. Our model demonstrated that NLP holds the potential to reduce clinician workloads, improve profitability, and, most importantly, make surgery safer.” Kevin Agatstein, CEO of KAID Health The International Anesthesia Research Society published the study, “Identification of Preanesthetic History Elements by a Natural Language Processing Engine,” in its journal, Anesthesia & Analgesia, one of the leading anesthesiology journals in the world. About KAID Health KAID Health makes care delivery more efficient, effective, and profitable for providers and their payers and Accountable Care Organization partners. Its Whole Chart Analysis platform extracts all relevant data from electronic medical records, including structured data and text, using artificial intelligence and natural language processing. The solution identifies the patient care interventions needed for providers to achieve their clinical, financial, or operational objectives. In parallel, KAID Health extends to payers a comprehensive view of members’ health by combining claims and EMR data. Today, KAID Health’s technology is used by leading providers, health systems, academic medical centers, and payers to automate a variety of workflows, including coding accuracy, quality measurement, prior authorization support, and pre-operative assessment. The company was founded by a veteran team of healthcare information technology and population health innovators. It is based in Boston, MA.

Read More

HEALTH TECHNOLOGY

athenahealth Implements DrFirst’s Digital Engagement Solution to Encourage Patients to Follow Prescribed Treatment Plans

athenahealth, Inc. | August 03, 2022

athenahealth, a leading provider of network-enabled software and services for medical groups and healthcare organizations nationwide, and health technology pioneer, DrFirst, today announced they are partnering to help improve medication adherence and patient outcomes. athenahealth’s large user base will now be able to send patient medication notifications powered by DrFirst’s RxInform to reduce prescription abandonment and help patients adhere to their recommended medication therapies. Patients abandon 20% to 30% of new prescriptions, whether due to high out-of-pocket costs, concerns about side effects, procrastination, or other factors. This lack of medication adherence can lead to increased total cost of patient care and undesirable health outcomes, such as disease progression, hospitalization, or even death. Now, the athenahealth electronic health record system that helps providers maximize clinical productivity and focus on delivering high-quality care to patients connects with RxInform, which automatically triggers a secure message to a patient’s mobile device when a clinician sends a prescription order to a pharmacy. From the message, patients may receive cost savings opportunities as available for a prescribed therapy and can view detailed information regarding their prescriptions, with a focus on behavioral and educational issues that have been proven to reduce prescription abandonment. The experience is seamless for the prescriber and helps them ensure the best outcomes for their patients. “We are always looking for innovative ways to drive better results for our customers and their patients – especially as the industry shifts more toward value-based care. Every provider wants to minimize prescription abandonment rates because non-adherence to medication regimens negatively affects desired clinical outcomes. By adding RxInform to the latest release of athenaOne, we are immediately giving all our providers an automated function within their established prescribing workflows to support better patient outcomes.” Paul Brient, chief product officer for athenahealth Since 2017, RxInform has received more than three million patient ratings, with 92% overall positive scores. These results indicate that patients welcome these messages, presenting new opportunities for providers to nurture patient relationships and build loyalty outside of the exam room. “Primary care providers and specialists who care for high-risk patients need tools to help people take their medications as prescribed,” said G. Cameron Deemer, president of DrFirst. “We’re pleased to partner with athenahealth to give its network of approximately 145,000 providers access to the RxInform platform so they can help patients overcome the common hurdles that lead them to abandon their medications at the pharmacy.” About athenahealth, Inc. athenahealth creates innovative healthcare technology that connects clinicians, patients, payers, and partners in differentiated ways. Our electronic health records, revenue cycle management, and patient engagement tools allow anytime, anywhere access, driving better financial outcomes for our customers and enabling our provider customers to deliver better quality care. In everything we do, we’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. About DrFirst Since 2000, DrFirst has pioneered healthcare technology solutions and consulting services that securely connect people at touchpoints of care to improve patient outcomes. We create unconventional solutions that solve care collaboration, medication management, price transparency, and adherence challenges faced in healthcare. We unite the Healthiverse—the interconnected healthcare universe—by providing our clients with real-time access to the information they need, exactly when and how they need it, so patients get the best care possible. DrFirst solutions are used by nearly 325,000 healthcare professionals, including 220,000 prescribers, 70,000 pharmacies, 290 HIS/EHRs, and 1,500 hospitals in the U.S. and Canada.

Read More

HEALTH TECHNOLOGY

BD Acquires MedKeeper to Offer Cloud-based, Connected Pharmacy Software

BD | July 29, 2022

BD a leading global medical technology company, announced today it has acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications. MedKeeper strategically complements BD's existing presence in the pharmacy – where the company has pioneered solutions in compounding, logistics workflow, controlled substance management and inventory optimization. MedKeeper's platform will become part of the company's existing portfolio of connected medication management capabilities. By combining MedKeeper's platform with BD's broad technology expertise, the companies will work to optimize the preparation of compounded medications – a critical need in the pharmacy today. "Preparing the right dose for patients requires a combination of factors – including personnel, training, and compliance. Pharmacy leaders require IV workflow management technology that is personalized to their needs and works within their environment. Adding MedKeeper to our portfolio will enable us to offer our customers easy to use, customizable solutions that make meaningful and incremental progress in IV workflow management." Mike Garrison, Worldwide President of Medication Management Solutions at BD Today, many pharmacies leverage a combination of both manual and technical tools for their IV workflow management system. Adding MedKeeper to BD's Medication Management Solutions portfolio will further strengthen the company's ability to deliver solutions that best meet customers' needs – now and in the future. "Demands in today's pharmacy environment, such as COVID-impacted labor shortages and changing regulatory requirements, have further exacerbated the need for customizable pharmacy software solutions to support flexible, directed workflow, inventory tracking and reporting needs in sterile and non-sterile compounding," said Garrison. "Manual, time-consuming procedures that might once have been 'good enough' now can be replaced and augmented by software that enables pharmacists to provide a higher standard of care." BD and MedKeeper will work to provide customers with flexibility and capabilities in meeting industry standards for preparing compounded medications, incorporating the latest regulatory guidance. Together, the companies are dedicated to ensuring that every customer has a workflow solution that best supports their environment and delivers efficiencies to their frontline clinicians. The transaction is expected to be immaterial to BD's fiscal 2022 financial results. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Read More

HEALTH TECHNOLOGY

KAID Health Technology Demonstrates the Value of Natural Language Processing to Improve Preoperative Care

KAID Health | August 02, 2022

KAID Health, an AI-powered health care data analysis and provider engagement platform, announced the results of a study that validates the potential utility of its Natural Language Processing technology to improve provider efficiency and care quality. The peer-reviewed “doctor vs. artificial intelligence” paper found that KAID Health’s NLP technology greatly aligned with the clinician reviewers in completing a pre-operative checklist, and further was able to identify 16.6% of instances where the presence or absence of a specific condition was not found by the anesthesiologist. The research study was undertaken at UCSD’s Department of Anesthesiology, Division of Perioperative Informatics. The authors of the manuscript were Harrison S. Suh, BS, Jeffrey L. Tully, MD, Minhthy N. Meineke, MD, Ruth S. Waterman, MD, MS, and Rodney A. Gabriel, MD, MAS. “We have demonstrated that NLP technology can help identify critical medical conditions relevant to preanesthetic evaluation. Key to this was KAID Health’s ability to utilize unstructured free-text input from the electronic medical record to flag critical medical conditions for anesthesiologists,” researcher and senior author Dr. Rodney Gabriel explained. “This research shows that NLP may be a useful tool to aid preoperative anesthesia providers in screening and evaluation of surgical patients.” For each of the 93 patients in the study, researchers collected all pertinent free-text notes from the EMR. The free-text notes were then processed by a Named Entity Recognition pipeline, which incorporated an NLP machine learning model developed by KAID Health. The model recognizes and labels spans of text that correspond to medical concepts. Medical concepts were then mapped to a list of medical conditions that were of interest for a preanesthesia evaluation. The most common conditions that the NLP pipeline captured that the anesthesiologist did not include cardiac arrhythmias, angina, anticoagulation, peripheral vascular disease, obstructive sleep apnea, and neuromuscular disease. “We are proud that leading academic institutions, such as UCSD, are partnering with KAID to ensure our NLP and AI models meet the demanding accuracy and usability standards required of the industry. KAID Health’s NLP technology played a vital role in this study in identifying pertinent preanesthesia history to optimize efficiency for anesthesiologists. Our model demonstrated that NLP holds the potential to reduce clinician workloads, improve profitability, and, most importantly, make surgery safer.” Kevin Agatstein, CEO of KAID Health The International Anesthesia Research Society published the study, “Identification of Preanesthetic History Elements by a Natural Language Processing Engine,” in its journal, Anesthesia & Analgesia, one of the leading anesthesiology journals in the world. About KAID Health KAID Health makes care delivery more efficient, effective, and profitable for providers and their payers and Accountable Care Organization partners. Its Whole Chart Analysis platform extracts all relevant data from electronic medical records, including structured data and text, using artificial intelligence and natural language processing. The solution identifies the patient care interventions needed for providers to achieve their clinical, financial, or operational objectives. In parallel, KAID Health extends to payers a comprehensive view of members’ health by combining claims and EMR data. Today, KAID Health’s technology is used by leading providers, health systems, academic medical centers, and payers to automate a variety of workflows, including coding accuracy, quality measurement, prior authorization support, and pre-operative assessment. The company was founded by a veteran team of healthcare information technology and population health innovators. It is based in Boston, MA.

Read More

Spotlight

UpLyft

UpLyft™ is the first known FDA-compliant Self Transfer System (“STS”) from bed to wheelchair for people with limited mobility. In 1 minute, a person can self-transfer him/herself with UpLyft™ from a flat (supine) position in bed into their wheelchair or vice versa. UpLyft™ replaces slings, body boar...

Events

Resources